Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Lansoprazole along with other OTC and Rx PPI ingredients were linked to a potential risk of acute generalized exanthematous pustulosis FDA in 2019 found a trend in adverse event reports.

FDA’s “Additional Condition for Nonprescription Use” proposal is all about information which won’t be printed on DFLs but will be integral to whether some switch proposals’ approval. But agency doesn’t explicitly exclude switch sponsors from assigning delivery of ACNU information to staff in stores or in online chats.

OTC drug development and marketing consultants discuss FDA allowing simultaneous Rx and OTC sales of same drug formulation with the same indication and about opportunities for follow-on generic equivalents of switches approved as additional condition for nonprescription use OTCs.

In this episode, HBW Insight speaks to Victoria Nichols, project director of Free the Pill, a campaign supporting increased OTC oral contraceptive access in the US. In the wake of the Supreme Court’s decision to overturn Roe v. Wade on 24 June, Nichols discusses the importance of advocating for OTC birth control, the limited availability of OTC oral contraceptives in the US, and the current legislation being introduced that would help ensure OTC birth control is covered by insurance. 

OTC drug development and marketing consultants spoke with HBW Insight about FDA’s “Nonprescription Drug Product with an Additional Condition for Nonprescription Use” proposed rule. In first of two articles, they discuss proposed rule’s likely impacts on industry and remaining concerns around incorporating extra-label information in drug labeling.

Certain rose, jasmine, cedarwood, freesia, lavender, apple, orange and musk fragrance ingredients could be eliminated purely on the basis of hazard if EU sustainable chemical principles are implemented as discussed across sectors and regulatory programs, according to Givaudan’s Greg Adamson, senior VP, global regulatory affairs and product safety for fragrance and beauty.

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

L’Oreal Group’s CEO referred VivaTech 2022 attendees to Yves Saint Laurent Beauty Scent-Sation, an electroencephalography-based headset that reads consumers’ emotional responses to different scent families, as an example of the firm’s beauty tech innovation that is personalizing the consumer experience, matching consumers with products, and distinguishing L’Oreal as a … err … “T-unicorn.”

Exactly what is in airbrush-delivered cosmetics, and how they are used by consumers, are not well understood by Cosmetic Ingredient Review, its expert panel, or the US FDA. At their June meeting, CIR’s independent experts debated who should be responsible for assessing airbrush cosmetics and how safety unknowns should be communicated.

The House Appropriations Committee asks the US Food and Drug Administration to provide a report to Congress in two years on the resources it would need to develop a database for fragrance allergens used in cosmetics. The committee’s report accompanying FY2023 FDA funding legislation also touches on OTC sunscreen regulation, PFAS in cosmetics, skin-lightening ingredients, and more.

The European Commission is preparing a legal proposal to revise the Cosmetic Products Regulation in line with Green Deal objectives, including the phasing out of chemicals deemed “most harmful." Cosmetics Europe director-general John Chave discusses the problematic approach, possible impacts, and the bizarre and unintended results it could produce.

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Lansoprazole along with other OTC and Rx PPI ingredients were linked to a potential risk of acute generalized exanthematous pustulosis FDA in 2019 found a trend in adverse event reports.

With its lateral flow at-home tests for ferritin, thyroid function and ovarian reserves, Swiss medtech firm Bloom Diagnostics thinks it has seen the future of consumer healthcare. HBW Insight speaks to co-founder and board chair Angelica Kohlmann about the firm's Bloom Lab technology and forward-looking plans, including a possible US launch. 

Nestlé Health Science continues to expand its dietary supplements offering in 2022 penning a deal for New Zealand's The Better Health Company and its GO Healthy brand. The company says the deal will strengthen its presence not just in New Zealand but across the wider APAC region in markets such as Australia and China.

A round-up of the latest European executive appointments: CRN UK hires scientific advisor; EMA management board names vice chair; Boots UK appoints chief digital officer.

System likely will evolve as post-pandemic world unfolds, but adds to list of agency programs expecting to continue using virtual platforms once in-person activities are no longer restricted by COVID-19.

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

In this episode, HBW Insight speaks to Victoria Nichols, project director of Free the Pill, a campaign supporting increased OTC oral contraceptive access in the US. In the wake of the Supreme Court’s decision to overturn Roe v. Wade on 24 June, Nichols discusses the importance of advocating for OTC birth control, the limited availability of OTC oral contraceptives in the US, and the current legislation being introduced that would help ensure OTC birth control is covered by insurance.